Melatonin: Difference between revisions
Notjusttired (talk | contribs) (outline, risks and safety, expand, tidy) |
Notjusttired (talk | contribs) (brand names, tidy) |
||
(91 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
[[File:Melatonin-sleep-tablets-OTC.jpg|alt=Two round white melatonin tablets next to a bottle of melatonin tablets.|thumb]] | [[File:Melatonin-sleep-tablets-OTC.jpg|alt=Two round white melatonin tablets next to a bottle of melatonin tablets.|thumb]] | ||
'''Melatonin''', also sold under the brand | '''Melatonin''', also sold under the brand names '''Circadin Adaflex''', '''Ceyesto''', '''Syncrodin''' and '''Slenyto''', is a hormone produced in the pineal gland which regulates sleep and wakefulness.<ref name="Hardeland2005">{{cite journal | author = Hardeland R | title = Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance | journal = Endocrine | volume = 27 | issue = 2 | pages = 119–30 | date = July 2005 | pmid = 16217125 | doi = 10.1385/ENDO:27:2:119 }}</ref><ref name="emc" /> It is involved in the synchronization of circadian rhythms, including sleep-wake timing, blood pressure and [[Temperature dysregulation|body temperature regulation]], cardiovascular efficiency and muscle strength, and many others.<ref name="Altun2007">{{cite journal |vauthors=Altun A, Ugur-Altun B | title = Melatonin: therapeutic and clinical utilization | journal = Int. J. Clin. Pract. | volume = 61 | issue = 5 | pages = 835–45 | date = May 2007 | pmid = 17298593 | doi = 10.1111/j.1742-1241.2006.01191.x }}</ref><ref name="hardeland2006">{{cite journal | vauthors = Hardeland R, Pandi-Perumal SR, Cardinali DP | title = Melatonin | journal = The International Journal of Biochemistry & Cell Biology | volume = 38 | issue = 3 | pages = 313–6 | date = March 2006 | pmid = 16219483 | doi = 10.1016/j.biocel.2005.08.020 }}</ref> | ||
==Theory == | ==Theory == | ||
Many of melatonin's biological effects are produced through activation of melatonin receptors,<ref name="Boutin2005">{{ | Many of melatonin's biological effects are produced through activation of melatonin receptors,<ref name="Boutin2005">{{Cite journal |vauthors=Boutin JA, Audinot V, Ferry G, Delagrange P | title = Molecular tools to study melatonin pathways and actions | journal = Trends Pharmacol. Sci. | volume = 26 | issue = 8 | pages = 412–19 | date = August 2005 | pmid = 15992934 | doi = 10.1016/j.tips.2005.06.006 }}</ref> while others are due to its role as an [[antioxidant]],<ref name="Hardeland2005" /> with a particular role in the protection of nuclear and [[mitochondria|mitochondrial]] DNA.<ref name="Reiter2001">{{citation |vauthors=Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S | title = Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system | journal = Ann. N. Y. Acad. Sci. | volume = 939 | issue = | pages = 200–15 | date = June 2001 | pmid = 11462772 | doi = 10.1111/j.1749-6632.2001.tb03627.x }}</ref> | ||
Melatonin supplements or medication are commonly used for helping people get to sleep or stay asleep.<ref name=drugscom>{{Cite web|url =http://www.drugs.com/melatonin.html|title =Melatonin|access-date =2021-03-04|website=drugs.com}}</ref><ref name="emc"/> | Melatonin over-the-counter supplements or medication are commonly used for helping people get to sleep or stay asleep.<ref name="drugscom">{{Cite web|url = http://www.drugs.com/melatonin.html| title = Melatonin|access-date = 2021-03-04 | website = drugs.com}}</ref><ref name="emc"/> | ||
==ME/CFS == | ==ME/CFS == | ||
Line 12: | Line 12: | ||
As a medicine, it is used for the treatment of [[insomnia]], however, scientific evidence is insufficient to demonstrate a benefit in this area.<ref name="Bra2015">{{citation | vauthors = Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ | title = Management of Insomnia Disorder [Internet] | date = December 2015 | pmid = 26844312 }}</ref> Melatonin is also used for [[sleep dysfunction]]. | As a medicine, it is used for the treatment of [[insomnia]], however, scientific evidence is insufficient to demonstrate a benefit in this area.<ref name="Bra2015">{{citation | vauthors = Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ | title = Management of Insomnia Disorder [Internet] | date = December 2015 | pmid = 26844312 }}</ref> Melatonin is also used for [[sleep dysfunction]]. | ||
As a medicine, some forms of melatonin are licensed for use for | As a medicine, some forms of melatonin are licensed for use for [[insomnia]] or sleep in children with ADHD.<ref name="emc"/> | ||
==Costs and availability== | ==Costs and availability== | ||
In [[Canada]] and the [[United States]], melatonin is sold over-the-counter. In other countries, such as the [[United Kingdom]], it is only available with a prescription but may be legal to import for personal use. | In [[Canada]] and the [[United States]], melatonin is sold over-the-counter. In other countries, such as the [[United Kingdom]], it is only available with a prescription but may be legal to import for personal use. | ||
==Dosage== | |||
Typical doseage for melatonin is 1-5mg per night.<ref name="emc" /> | |||
==Risks and safety == | ==Risks and safety == | ||
Melatonin | Melatonin should only be used after doctor's advice in people with an [[autoimmune disorder|autoimmune disease],<ref name="emc">{{Cite web | title = Slenyto 5 mg prolonged-release tablets|website=electronic medicines compendium |access-date = Mar 4, 2021|url=https://emc-prod-ukwest-wa.azurewebsites.net/emc/product/10024/smpc}}</ref> however ME/CFS is not classed as an autoimmune disease at present despite the presence of some [[:Category:Immune signs and symptoms|immune symptoms]].<ref name="ICC2011primer">{{Cite journal | last1 = Carruthers | first1 = BM | authorlink1 = Bruce Carruthers | last2 = van de Sande | first2 = MI | authorlink2 = Marjorie van de Sande | last3 = De Meirleir | first3 = KL | authorlink3 = Kenny de Meirleir | last4 = Klimas | first4 = NG | authorlink4 = Nancy Klimas | last5 = Broderick | first5 = G | authorlink5 = Gordon Broderick | last6 = Mitchell | first6 = T | authorlink6 = Terry Mitchell | last7 = Staines | first7 = D | authorlink7 = Donald Staines | last8 = Powles | first8 = ACP | authorlink8 = A C Peter Powles | last9 = Speight | first9 = N | authorlink9 = Nigel Speight | last10 = Vallings | first10 = R | authorlink10 = Rosamund Vallings | last11 = Bateman | first11 = L | authorlink11 = Lucinda Bateman | last12 = Bell | first12 = DS | authorlink12 = David Bell | last13 = Carlo-Stella | first13 = N | authorlink13 = Nicoletta Carlo-Stella | last14 = Chia | first14 = J | authorlink14 = John Chia | last15 = Darragh | first15 = A | authorlink15 = Austin Darragh | last16 = Gerken | first16 = A | authorlink16 = Anne Gerken | last17 = Jo | first17 = D | authorlink17 = Daehyun Jo | last18 = Lewis | first18 = DP | authorlink18 = Donald Lewis | last19 = Light | first19 = AR | authorlink19 = Alan Light | last20 = Light | first20 = KC | authorlink20 = Kathleen Light | last21 = Marshall-Gradisnik | first21 = S | authorlink21 = Sonya Marshall-Gradisnik | last22 = McLaren-Howard | first22 = J | authorlink22 = John McLaren-Howard | last23 = Mena | first23 = I | authorlink23 = Ismael Mena | last24 = Miwa | first24 = K | authorlink24 = Kunihisa Miwa | last25 = Murovska | first25 = M | authorlink25= Modra Murovska | last26 = Stevens | first26 = SR | authorlink26 = Staci Stevens | title = Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners | date = 2012| isbn = 978-0-9739335-3-6 | url = http://www.investinme.org/Documents/Guidelines/Myalgic%20Encephalomyelitis%20International%20Consensus%20Primer%20-2012-11-26.pdf }}</ref><ref name="ICD11">{{cite web | title = ICD-11 - Mortality and Morbidity Statistics|url=https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f569175314 | last = World Health Organization | first = | authorlink = World Health Organization | date = 2020 | website = icd.who.int|url-status=|archive-url=|archive-date=|access-date=20 May 2020|quote=Diseases of the nervous system}}</ref><ref name="CDC-IOM-SEIDcriteria">{{Cite web|url=https://www.cdc.gov/me-cfs/healthcare-providers/diagnosis/iom-2015-diagnostic-criteria.html | title = IOM 2015 Diagnostic Criteria {{!}} Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|website=[[Centers for Disease Control and Prevention]] | date = Jan 27, 2021|access-date = 2021-02-25}}</ref> | ||
| last3 = De Meirleir | first3 = KL | authorlink3 = Kenny de Meirleir | |||
| last4 = Klimas | first4 = NG | authorlink4 = Nancy Klimas| last5 = Broderick | first5 = G | authorlink5 = Gordon Broderick | ===Side effects === | ||
| last6 = Mitchell | first6 = T | authorlink6 = Terry Mitchell | Melatonin side effects are usually mild, these can include: | ||
| last7 = Staines | first7 = D | authorlink7 = Donald Staines| last8 = Powles | first8 = ACP | authorlink8 = A C Peter Powles | *[[Daytime sleepiness]]/tiredness | ||
| last9 = Speight | first9 = N | authorlink9 = Nigel Speight| last10 = Vallings | first10= R | authorlink10= Rosamund Vallings | *[[Headache]]s | ||
| last11 = Bateman | first11= L | authorlink11= Lucinda Bateman | *[[Stomach pain|stomach ache]] | ||
| last12 = Bell | first12= DS | authorlink12= David Bell | *[[Nausea]] | ||
| last13 = Carlo-Stella | first13= N | authorlink13= Nicoletta Carlo-Stella | *[[Dizziness]] | ||
| last14 = Chia | first14= J | authorlink14= John Chia| last15 = Darragh | first15= A | authorlink15= Austin Darragh | *[[Irritability]] or restlessness | ||
| last16 = Gerken | first16= A | authorlink16= Anne Gerken | *[[Dry mouth]] | ||
| last17 = Jo | first17= D | authorlink17= Daehyun Jo| last18 = Lewis | first18= DP | authorlink18= Donald Lewis | *[[Dry skin|Dry]] or [[skin itch|itchy skin]] | ||
| last19 = Light | first19= AR | authorlink19= Alan Light | *[[Pain]]s in your arms or legs | ||
| last20 = Light | first20= KC | authorlink20= Kathleen Light | *Strange or vivid dreams | ||
| last21 = Marshall-Gradisnik | first21= S | authorlink21= Sonya Marshall-Gradisnik | *Night sweats<ref name="NHS">{{Cite web | url = https://www.nhs.uk/medicines/melatonin/side-effects-of-melatonin/| title = Side effects of melatonin| website= NHS|access-date=2023-12-31}}</ref><ref name="drugscom"/> | ||
| last22 = McLaren-Howard | first22= J | authorlink22= John McLaren-Howard | |||
| last23 = Mena | first23= I | authorlink23= Ismael Mena| last24 = Miwa | first24= K | authorlink24= Kunihisa Miwa| last25 = Murovska | first25= M | authorlink25= Modra Murovska| last26 = Stevens | first26= SR | authorlink26= Staci Stevens | |||
| title = Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners | |||
| date = 2012| isbn = 978-0-9739335-3-6 | |||
| url = http://www.investinme.org/Documents/Guidelines/Myalgic%20Encephalomyelitis%20International%20Consensus%20Primer%20-2012-11-26.pdf | |||
}}</ref><ref name="ICD11">{{cite web|title=ICD-11 - Mortality and Morbidity Statistics|url=https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f569175314|last=World Health Organization|first=|authorlink=World Health Organization|date=2020|website=icd.who.int|url-status=|archive-url=|archive-date=| | |||
==Notable studies== | ==Notable studies== | ||
*1996, [https://www.ncbi.nlm.nih.gov/pubmed/8842569 Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome]<ref name="melationincfs1996">{{ | *1996, [https://www.ncbi.nlm.nih.gov/pubmed/8842569 Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome]<ref name="melationincfs1996">{{Cite journal | issn = 0144-5979| volume = 16 | issue = 4| pages = 327–337| last1 = Williams | first1 = G. | last2 = Pirmohamed | first2 = J. | last3 = Minors | first3 = D. | last4 = Waterhouse | first4 = J. | last5 = Buchan | first5 = I. | last6 = Arendt | first6 = J. | last7 = Edwards | first7 = R.H. | title = Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome| journal = Clinical Physiology (Oxford, England)| date = July 1996 | pmid = 8842569}}</ref> | ||
* 2016, [https://www.ncbi.nlm.nih.gov/pubmed/27226183 Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.]<ref name="melatoninms2016">{{ | * 2016, [https://www.ncbi.nlm.nih.gov/pubmed/27226183 Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.]<ref name="melatoninms2016">{{Cite journal | issn = 1899-1505| volume = 67 | issue = 2| pages = 235–242| last1 = Adamczyk-Sowa | first1 = M. | last2 = Sowa | first2 = P. | last3 = Adamczyk | first3 = J. | last4 = Niedziela | first4 = N. | last5 = Misiolek | first5 = H. | last6 = Owczarek | first6 = M. | last7 = Zwirska-Korczala | first7 = K.| title = Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone| journal = Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society | date = April 2016 | pmid = 27226183}}</ref> | ||
==News articles == | |||
* 2023, [https://edition.cnn.com/2022/02/01/health/melatonin-overuse-wellness/index.html Using melatonin for sleep is on the rise, study says, despite potential health harms] - CNN | |||
==Learn more== | ==Learn more== | ||
Line 56: | Line 56: | ||
[[Category:Potential treatments]] | [[Category:Potential treatments]] | ||
[[Category:Non-benzodiazepine hypnotics]] | [[Category:Non-benzodiazepine hypnotics]] | ||
[[Category: | [[Category:Sleep aids and hypnotics]] |
Latest revision as of 22:35, December 31, 2023
Melatonin, also sold under the brand names Circadin Adaflex, Ceyesto, Syncrodin and Slenyto, is a hormone produced in the pineal gland which regulates sleep and wakefulness.[1][2] It is involved in the synchronization of circadian rhythms, including sleep-wake timing, blood pressure and body temperature regulation, cardiovascular efficiency and muscle strength, and many others.[3][4]
Theory[edit | edit source]
Many of melatonin's biological effects are produced through activation of melatonin receptors,[5] while others are due to its role as an antioxidant,[1] with a particular role in the protection of nuclear and mitochondrial DNA.[6]
Melatonin over-the-counter supplements or medication are commonly used for helping people get to sleep or stay asleep.[7][2]
ME/CFS[edit | edit source]
Evidence[edit | edit source]
As a medicine, it is used for the treatment of insomnia, however, scientific evidence is insufficient to demonstrate a benefit in this area.[8] Melatonin is also used for sleep dysfunction.
As a medicine, some forms of melatonin are licensed for use for insomnia or sleep in children with ADHD.[2]
Costs and availability[edit | edit source]
In Canada and the United States, melatonin is sold over-the-counter. In other countries, such as the United Kingdom, it is only available with a prescription but may be legal to import for personal use.
Dosage[edit | edit source]
Typical doseage for melatonin is 1-5mg per night.[2]
Risks and safety[edit | edit source]
Melatonin should only be used after doctor's advice in people with an [[autoimmune disorder|autoimmune disease],[2] however ME/CFS is not classed as an autoimmune disease at present despite the presence of some immune symptoms.[9][10][11]
Side effects[edit | edit source]
Melatonin side effects are usually mild, these can include:
- Daytime sleepiness/tiredness
- Headaches
- stomach ache
- Nausea
- Dizziness
- Irritability or restlessness
- Dry mouth
- Dry or itchy skin
- Pains in your arms or legs
- Strange or vivid dreams
- Night sweats[12][7]
Notable studies[edit | edit source]
- 1996, Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome[13]
- 2016, Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.[14]
News articles[edit | edit source]
Learn more[edit | edit source]
- Drugs.com - Melatonin
- Wikipedia - Melatonin
References[edit | edit source]
- ↑ 1.0 1.1 Hardeland R (July 2005). "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine. 27 (2): 119–30. doi:10.1385/ENDO:27:2:119. PMID 16217125.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Slenyto 5 mg prolonged-release tablets". electronic medicines compendium. Retrieved March 4, 2021.
- ↑ Altun A, Ugur-Altun B (May 2007). "Melatonin: therapeutic and clinical utilization". Int. J. Clin. Pract. 61 (5): 835–45. doi:10.1111/j.1742-1241.2006.01191.x. PMID 17298593.
- ↑ Hardeland R, Pandi-Perumal SR, Cardinali DP (March 2006). "Melatonin". The International Journal of Biochemistry & Cell Biology. 38 (3): 313–6. doi:10.1016/j.biocel.2005.08.020. PMID 16219483.
- ↑ Boutin JA, Audinot V, Ferry G, Delagrange P (August 2005). "Molecular tools to study melatonin pathways and actions". Trends Pharmacol. Sci. 26 (8): 412–19. doi:10.1016/j.tips.2005.06.006. PMID 15992934.
- ↑ Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S (June 2001), "Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system", Ann. N. Y. Acad. Sci., 939: 200–15, doi:10.1111/j.1749-6632.2001.tb03627.x, PMID 11462772
- ↑ 7.0 7.1 "Melatonin". drugs.com. Retrieved March 4, 2021.
- ↑ Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ (December 2015), Management of Insomnia Disorder [Internet], PMID 26844312
- ↑ Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012). "Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners" (PDF). ISBN 978-0-9739335-3-6. Cite journal requires
|journal=
(help) - ↑ World Health Organization (2020). "ICD-11 - Mortality and Morbidity Statistics". icd.who.int. Retrieved May 20, 2020.
Diseases of the nervous system
- ↑ "IOM 2015 Diagnostic Criteria | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Centers for Disease Control and Prevention. January 27, 2021. Retrieved February 25, 2021.
- ↑ "Side effects of melatonin". NHS. Retrieved December 31, 2023.
- ↑ Williams, G.; Pirmohamed, J.; Minors, D.; Waterhouse, J.; Buchan, I.; Arendt, J.; Edwards, R.H. (July 1996). "Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome". Clinical Physiology (Oxford, England). 16 (4): 327–337. ISSN 0144-5979. PMID 8842569.
- ↑ Adamczyk-Sowa, M.; Sowa, P.; Adamczyk, J.; Niedziela, N.; Misiolek, H.; Owczarek, M.; Zwirska-Korczala, K. (April 2016). "Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone". Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society. 67 (2): 235–242. ISSN 1899-1505. PMID 27226183.